Erlotinib in the treatment of advanced pancreatic cancer.
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in combination have yielded disappointing results, spurring the ongoing search for new agents and combinations in this aggressive malignancy. Inhibitors of the epidermal growth factor receptor (EGFR) have shown promising activity in multiple solid tumors types, and preclinical data support a role for EGFR inhibition in pancreatic cancer. A recent phase III study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) demonstrated a significant survival benefit with the addition of the EGFR tyrosine kinase inhibitor, erlotinib, to gemcitabine chemotherapy for the first-line treatment of patients with advanced pancreatic cancer, becoming the first phase III study to demonstrate a survival benefit of combination therapy as well as targeted therapy in this disease. This article reviews the evidence supporting EGFR inhibition and the use of erlotinib in advanced pancreatic cancer as well as future implications of targeted therapy in this challenging malignancy.
Kelley
Robin K
RK
University of California, San Francisco, Comprehensive Cancer Center.
Ko
Andrew H
AH
Cancer Res. 1999 Apr 15;59(8):1935-40
10213503
Pancreas. 2004 Jul;29(1):e1-8
15211117
J Clin Oncol. 2005 Aug 1;23(22):5235-46
16051966
J Clin Oncol. 2009 Nov 20;27(33):5513-8
19858379
Cancer Res. 2000 Jun 1;60(11):2926-35
10850439
Mol Biol Cell. 1999 Aug;10(8):2493-506
10436007
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
J Clin Oncol. 2005 Mar 20;23(9):1803-10
15677699
JAMA. 2007 Jan 17;297(3):267-77
17227978
J Natl Cancer Inst. 2005 May 4;97(9):643-55
15870435
J Clin Oncol. 2006 Sep 20;24(27):4441-7
16983112
Pharmacol Ther. 2004 Apr;102(1):37-46
15056497
Dig Surg. 2006;23(1-2):74-9
16717472
J Clin Oncol. 2004 Sep 15;22(18):3776-83
15365074
Ann Oncol. 2008 Jan;19(1):86-91
17878176
Int J Cancer. 2007 Feb 1;120(3):514-23
17096356
Anticancer Res. 1993 May-Jun;13(3):565-9
8317885
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7
16857803
Crit Rev Oncol Hematol. 2008 May;66(2):155-62
18083041
Br J Cancer. 2001 Apr 6;84(7):926-35
11286473
Cancer. 2006 Sep 15;107(6):1207-18
16909423
J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S
11560969
Ann Oncol. 2005 Sep;16(9):1425-33
16012181
J Clin Oncol. 2002 Aug 1;20(15):3270-5
12149301
Int J Oncol. 2004 Jul;25(1):203-10
15202007
J Clin Oncol. 2005 Sep 1;23(25):5900-9
16043828
Surgery. 2007 Apr;141(4):464-9
17383523
Cancer. 2007 Apr 15;109(8):1561-9
17354229
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002093
16855985
J Clin Oncol. 2007 May 20;25(15):1960-6
17452677
J Clin Oncol. 2007 Apr 20;25(12):1545-52
17442998
J Pharmacol Exp Ther. 1999 Nov;291(2):739-48
10525095
J Clin Oncol. 2006 Mar 1;24(7):1219-20; author reply 1220-1
16505443
JOP. 2007 Jan 09;8(1):4-15
17228128
J Surg Res. 2006 Sep;135(1):195-201
16678855
Cancer Res. 1997 Nov 1;57(21):4838-48
9354447
Ann Surg Oncol. 2007 Jul;14(7):2150-8
17453292
J Clin Oncol. 2005 Oct 1;23(28):6829-37
15998907
Clin Cancer Res. 2001 Mar;7(3):682-90
11297265
Int J Mol Med. 2003 Mar;11(3):305-9
12579331
J Clin Oncol. 2004 Jan 1;22(1):77-85
14701768
J Clin Oncol. 2005 Nov 1;23(31):8081-92
16204011
Cancer Chemother Pharmacol. 2007 Jul;60(2):295-303
17149608
J Clin Oncol. 2007 Jun 1;25(16):2212-7
17538165
Mol Cancer Ther. 2002 Aug;1(10):777-83
12492110
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9
16626884
J Clin Oncol. 2006 Oct 20;24(30):4914-21
17050875
J Clin Oncol. 2001 Jul 1;19(13):3267-79
11432895
Oncogene. 1997 Sep 4;15(10):1191-7
9294612
Science. 2004 Jun 4;304(5676):1497-500
15118125
J Clin Oncol. 2023 Oct 20;41(30):4714-4720
37847995
Ann Oncol. 2007 Oct;18(10):1652-9
17660491
Ann Oncol. 2007 Apr;18(4):752-60
17317677
Clin Cancer Res. 2007 Jul 1;13(13):3913-21
17606725
J Clin Oncol. 2007 Jun 1;25(16):2248-55
17538169
J Clin Oncol. 2005 May 20;23(15):3509-16
15908661
J Clin Oncol. 2005 Oct 1;23(28):6838-45
15998906
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
J Natl Cancer Inst. 2003 Jun 18;95(12):851-67
12813169
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
J Clin Oncol. 2005 Apr 10;23(11):2556-68
15767641